This morning, Compass Pathways announced that it now expects to provide a top-line readout from its first phase 3 study (COMP005) of its psilocybin candidate (COMP360) in treatment-resistant depression (TRD) in Q2’25, and a readout from its second, two-dose phase 3 study (COMP006) in H2’26. The company also announced a corporate restructuring that sees it shed nearly a third of its workforce along…
